COMMUNIQUÉS West-GlobeNewswire

Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
11/11/2018
ODYSSEY OUTCOMES investigators highlight at AHA that Praluent ® (alirocumab) was associated with fewer deaths from any cause Mortality risk reduction greater in patients treated for at least 3 years or those with [...]
Sanofi : Au Congrès de l'AHA, les investigateurs d'ODYSSEY OUTCOMES présentent des données montrant que Praluent® (alirocumab) a été associé à un nombre réduit de décès toutes causes confondues
11/11/2018
Au Congrès de l'AHA, les investigateurs d'ODYSSEY OUTCOMES présentent des données montrant que Praluent ® (alirocumab) a été associé à un nombre réduit de décès toutes causes confondues Une réduction du risque de [...]
Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting
10/11/2018
CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab Novel adenosine gene signature biomarker associated with response to [...]
AI Algorithm Outperformed Majority of Cardiologists in Detection of Heart Murmurs in Clinical Study
10/11/2018
Eko’s heart murmur detection algorithm outperformed four out of five cardiologists for the detection of heart murmurs in a recent clinical study. The algorithm is designed to empower four million U.S. clinicians to [...]
ACC, AHA Release 2018 Guideline on the Management of Blood Cholesterol at AHA Scientific Sessions
10/11/2018
NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease CHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) -- The American College of Cardiology and American Heart [...]
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
10/11/2018
- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: [...]
Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy
10/11/2018
AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10 Significantly Raised [...]
Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
10/11/2018
Antibody technology provides an exciting new approach to enhance innate immune function in cancer HAMPTON, N.J., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company [...]
G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
10/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial [...]
Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for KAIYADRU®. Hoverink Biotechnologies, Inc plans to develop and commercialize KAIYADRU®
10/11/2018
Overview On September 26, 2018 We filed trademark applications covering: LOS ANGELES, CA, Nov. 09, 2018 (GLOBE NEWSWIRE) -- KAIYADRU® Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of [...]
HEXO announces filing of preliminary base shelf prospectus
09/11/2018
GATINEAU, Quebec, Nov. 09, 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities [...]
HEXO annonce le dépôt d’un prospectus préalable de base provisoire
09/11/2018
GATINEAU, Québec, 09 nov. 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO) a annoncé le dépôt d’un prospectus préalable de base simplifié provisoire auprès des autorités de réglementation en [...]
MacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting
09/11/2018
Enoblituzumab + pembrolizumab combination study data reported: ORRs in anti-PD-1/PD-L1 naïve SCCHN and NSCLC cohorts benchmarked favorably vs. approved anti-PD-1 agents Interim data from Phase 1 dose expansion study of [...]
Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
09/11/2018
SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update. Dr. Dennis J. Carlo [...]
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information
09/11/2018
Conference Call Scheduled for Monday, November 12 th at 11:30 AM EST NORTHVALE, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical [...]
Atrion Reports Third Quarter Results
09/11/2018
ALLEN, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that for the third quarter ended September 30, 2018 revenues totaled $39.3 million, up from $37.9 million for the same [...]
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
09/11/2018
Investor Conference Call on Monday, November 12 th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company [...]
Asterias Biotherapeutics Reports Third Quarter Results
09/11/2018
Clinical Programs Continue to Progress Recent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating Expenses Recently Announced Definitive Merger Agreement with BioTime Creates [...]
Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent [...]

Pages